Thermo Fisher's 15min chart triggers MACD Death Cross, KDJ Death Cross warning.
ByAinvest
Tuesday, Sep 23, 2025 10:04 am ET1min read
TMO--
The stock price decreased by 1.1% to $474.54, with a market capitalization of $179.19 billion and a price-to-earnings ratio of 27.45. This decline comes amidst several institutional adjustments in the company's stock holdings. Pictet North America Advisors SA reduced its holdings by 15.1%, owning 7,630 shares valued at approximately $3.09 million [1].
Other notable institutional changes include Mondrian Investment Partners LTD, which increased its holdings by 146.1%, now owning 214,506 shares valued at $106,738,000, and Foresight Group Ltd Liability Partnership, which boosted its holdings by 3,242.7%, owning 58,497 shares valued at $29,113,000 [1]. Meanwhile, Park Avenue Securities LLC cut its position by 22.2%, holding 11,926 shares valued at $4,836,000 [2].
These changes reflect a broader trend in institutional sentiment towards Thermo Fisher Scientific. Despite recent earnings results that exceeded analyst expectations, with earnings per share (EPS) of $5.36 for the quarter, the company's guidance for the third quarter of 2025 and fiscal year 2025 was met with cautious optimism. Analysts have set new price targets, with a mix of "Buy," "Hold," and "Outperform" ratings, indicating a varied outlook on the stock's future performance [1].
Insider trading also played a role in the recent stock movements. Executive Vice President Gianluca Pettiti sold 400 shares, and CEO Marc N. Casper sold 400 shares, resulting in a combined reduction of 0.33% of the stock owned by insiders [1].
Investors should closely monitor these developments and consider the potential implications of the "death cross" signals and institutional adjustments on Thermo Fisher Scientific's stock price. The company's ongoing financial performance and strategic initiatives will be crucial in determining its future trajectory.
According to Thermo Fisher's 15-minute chart, the MACD and KDJ indicators have both triggered "death crosses" at 10:00 on September 23, 2025. This indicates that the stock price has the potential to continue declining, as the momentum of the stock price is shifting towards the downside and could potentially lead to further decreases.
On September 23, 2025, Thermo Fisher Scientific Inc. (NYSE: TMO) experienced a significant drop in its stock price, triggered by the "death cross" signals from the MACD and KDJ indicators on its 15-minute chart. This technical indicator suggests a potential continuation of the stock's downward trend, as the momentum is shifting towards the downside [1].The stock price decreased by 1.1% to $474.54, with a market capitalization of $179.19 billion and a price-to-earnings ratio of 27.45. This decline comes amidst several institutional adjustments in the company's stock holdings. Pictet North America Advisors SA reduced its holdings by 15.1%, owning 7,630 shares valued at approximately $3.09 million [1].
Other notable institutional changes include Mondrian Investment Partners LTD, which increased its holdings by 146.1%, now owning 214,506 shares valued at $106,738,000, and Foresight Group Ltd Liability Partnership, which boosted its holdings by 3,242.7%, owning 58,497 shares valued at $29,113,000 [1]. Meanwhile, Park Avenue Securities LLC cut its position by 22.2%, holding 11,926 shares valued at $4,836,000 [2].
These changes reflect a broader trend in institutional sentiment towards Thermo Fisher Scientific. Despite recent earnings results that exceeded analyst expectations, with earnings per share (EPS) of $5.36 for the quarter, the company's guidance for the third quarter of 2025 and fiscal year 2025 was met with cautious optimism. Analysts have set new price targets, with a mix of "Buy," "Hold," and "Outperform" ratings, indicating a varied outlook on the stock's future performance [1].
Insider trading also played a role in the recent stock movements. Executive Vice President Gianluca Pettiti sold 400 shares, and CEO Marc N. Casper sold 400 shares, resulting in a combined reduction of 0.33% of the stock owned by insiders [1].
Investors should closely monitor these developments and consider the potential implications of the "death cross" signals and institutional adjustments on Thermo Fisher Scientific's stock price. The company's ongoing financial performance and strategic initiatives will be crucial in determining its future trajectory.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet